文献速递消化系统肿瘤

APX005M联合化疗±纳武利尤单抗治疗转移性胰腺腺癌的1b期研究

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
PubMed 文献 · Lancet Oncol · 2021-01-01

这项非随机、开放标签、多中心、四队列1b期研究评估了APX005M联合吉西他滨+白蛋白紫杉醇±纳武利尤单抗治疗初治转移性胰腺腺癌的安全性。30例患者入组,24例可评估剂量限制毒性(DLT),常见3-4级治疗相关不良事件为淋巴细胞减少(67%)、贫血(37%)和中性粒细胞减少(30%)。

要点

  • APX005M联合吉西他滨+白蛋白紫杉醇±纳武利尤单抗在转移性胰腺腺癌中可耐受。
  • DLT可评估人群客观缓解率达58%(14/24),显示临床活性。

核心结论

  • APX005M联合吉西他滨+白蛋白紫杉醇±纳武利尤单抗在转移性胰腺腺癌中可耐受并显示临床活性。

研究设计与样本

  • 非随机、开放标签、多中心、四队列1b期研究,在美国7家学术医院进行。
  • 纳入30例初治转移性胰腺腺癌成人患者(ECOG 0-1,可测量病灶),均接受吉西他滨1000 mg/m2+白蛋白紫杉醇125 mg/m2。
  • 主要终点为不良事件发生率、DLT发生率和推荐2期剂量;24例可评估DLT。

主要发现

  • 观察到2例DLT(均为发热性中性粒细胞减少),分别发生在队列B2(3级)和C1(4级)各1例。
  • 最常见3-4级治疗相关不良事件为淋巴细胞减少(20/30,67%)、贫血(11/30,37%)和中性粒细胞减少(9/30,30%)。
  • 14/30(47%)患者发生治疗相关严重不良事件,最常见为发热(6/30,20%)。
  • 发生2例化疗相关死亡(B1组1例脓毒症,C1组1例感染性休克)。
  • DLT可评估人群中14/24(58%)观察到缓解。

关键数值与推荐

  • DLT可评估人群客观缓解率为58%(14/24)。

临床怎么用

  • 该联合方案在转移性胰腺腺癌中具有可接受的安全性和初步抗肿瘤活性。
  • 若后续期试验证实,该方案可能替代单纯化疗的标准治疗。

局限性

  • 非随机、开放标签、小样本1b期研究,结果需后期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard chemotherapy remains inadequate in metastatic pancreatic adenocarcinoma. Combining an agonistic CD40 monoclonal antibody with chemotherapy induces T-cell-dependent tumour regression in mice and improves survival. In this study, we aimed to evaluate the safety of combining APX005M (sotigalimab) with gemcitabine plus nab-paclitaxel, with and without nivolumab, in patients with pancreatic adenocarcinoma to establish the recommended phase 2 dose. METHODS: This non-randomised, open-label, multicentre, four-cohort, phase 1b study was done at seven academic hospitals in the USA. Eligible patients were adults aged 18 years and older with untreated metastatic pancreatic adenocarcinoma, Eastern Cooperative Oncology Group performance status score of 0-1, and measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1. All patients were treated with 1000 mg/m2 intravenous gemcitabine and 125 mg/m2 intravenous nab-paclitaxel. Patients received 0·1 mg/kg intravenous APX005M in cohorts B1 and C1 and 0·3 mg/kg in cohorts B2 and C2. In cohorts C1 and C2, patients also received 240 mg intravenous nivolumab. Primary endpoints comprised incidence of adverse events in all patients who received at least one dose of any study drug, incidence of dose-limiting toxicities (DLTs) in all patients who had a DLT or received at least two doses of gemcitabine plus nab-paclitaxel and one dose of APX005M during cycle 1, and establishing the recommended phase 2 dose of intravenous APX005M. Objective response rate in the DLT-evaluable population was a key secondary endpoint. This trial (PRINCE, PICI0002) is registered with ClinicalTrials.gov, NCT03214250 and is ongoing. FINDINGS: Between Aug 22, 2017, and July 10, 2018, of 42 patients screened, 30 patients were enrolled and received at least one dose of any study drug; 24 were DLT-evaluable with median follow-up 17·8 months (IQR 16·0-19·4; cohort B1 22·0 months [21·4-22·7], cohort B2 18·2 months [17·0-18·9], cohort C1 17·9 months [14·3-19·7], cohort C2 15·9 months [12·7-16·1]). Two DLTs, both febrile neutropenia, were observed, occurring in one patient each for cohorts B2 (grade 3) and C1 (grade 4). The most common grade 3-4 treatment-related adverse events were lymphocyte count decreased (20 [67%]; five in B1, seven in B2, four in C1, four in C2), anaemia (11 [37%]; two in B1, four in B2, four in C1, one in C2), and neutrophil count decreased (nine [30%]; three in B1, three in B2, one in C1, two in C2). 14 (47%) of 30 patients (four each in B1, B2, C1; two in C2) had a treatment-related serious adverse event. The most common serious adverse event was pyrexia (six [20%] of 30; one in B2, three in C1, two in C2). There were two chemotherapy-related deaths due to adverse events: one sepsis in B1 and one septic shock in C1. The recommended phase 2 dose of APX005M was 0·3 mg/kg. Responses were observed in 14 (58%) of 24 DLT-evaluable patients (four each in B1, C1, C2; two in B2). INTERPRETATION: APX005M and gemcitabine plus nab-paclitaxel, with or without nivolumab, is tolerable in metastatic pancreatic adenocarcinoma and shows clinical activity. If confirmed in later phase trials, this treatment regimen could replace chemotherapy-only standard of care in this population. FUNDING: Parker Institute for Cancer Immunotherapy, Cancer Research Institute, and Bristol Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. O'Hara MH, O'Reilly EM, Varadhachary G, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021. PMID: 33387490. doi:10.1016/S1470-2045(20)30532-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。